title: Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use.
authors.affiliation: Department of Anesthesiology and Health Policy, Management, and Evaluation, Toronto General Hospital, 200 Elizabeth St., 3EN-402, Toronto, Ontario, Canada M5G 2C4. keyvan.karkouti@uhn.on.ca
authors.forename: Keyvan
authors.initials: K
authors.lastname: Karkouti
authors.forename: Jerrold H
authors.initials: JH
authors.lastname: Levy
mesh_terms: D000077144:Clopidogrel; D015942:Factor VIIa / Q000627:therapeutic use*; D006470:Hemorrhage / Q000188:drug therapy*; D006487:Hemostasis / Q000187:drug effects*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D006490:Hemostatics; D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; D000077144:Clopidogrel; C103587:recombinant FVIIa; D015942:Factor VIIa; D013988:Ticlopidine